Stephen Ellis on Questions Passed as Orders for Returns

With regard to Health Canada's position on the practice of repackaging single use medications to treat macular degeneration, since 2016: (a) does Health Canada allow the practice; (b) what risks does Health Canada recognize as existing with the practice; (c) has Health Canada studied the risks associated with the practice related to (i) sterility, (ii) cold chain protection, (iii) ultraviolet light protection, (iv) accurate dosing, (v) contamination, (vi) transportation issues, and, if so, what were the findings related to each risk; (d) has Health Canada or the Minister of Health received any warnings or correspondence indicating or suggesting that the practice is occurring in Canada, and, if so, what are the details, including the (i) date, (ii) author of the warning or correspondence, (iii) summary of warning or correspondence, (iv) recipient, (v) summary of response given by Health Canada or the Minister's office; and (e) for each warning or correspondence that was received in (d), what follow-up action was taken?